Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343368 · ClinicalTrials.gov registry record · Phase 2
Preservation of Ovarian Function After Hematopoietic Cell Transplant
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01343368 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 19 participants.
The verdict
NCT01343368, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
Interventions
- DRUG Leuprolide
- BIOLOGICAL hematopoietic cell transplant
- BIOLOGICAL reduced intensity allogeneic HCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01343368
The ClinicalTrials.gov registry entry for NCT01343368 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Leuprolide is the first listed.
NCT01343368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01343368 about?
NCT01343368 is a clinical study titled "Preservation of Ovarian Function After Hematopoietic Cell Transplant". Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
What is the current status of trial NCT01343368?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2011-07. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01343368?
The interventions under investigation include: Leuprolide (DRUG), hematopoietic cell transplant (BIOLOGICAL), reduced intensity allogeneic HCT (BIOLOGICAL).
Who is sponsoring clinical trial NCT01343368?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.